Compd | P-gp substrates | CYP1A2 inhibitor | CYP2C9 inhibitor | CYP2C19 inhibitor | CYP2D6 inhibitor | CYP3A4 inhibitor | Ames | hERG | Caco-2 | PPB | CNS | HIA | Metabolic stability |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 0.48 | 0.29 | 0.46 | 0.43 | 0.39 | 0.48 | 0.35 | 0.36 | 234.1 | 71 | − 1.73 | 100 | 0.51 |
2 | 0.50 | 0.28 | 0.45 | 0.42 | 0.37 | 0.45 | 0.34 | 0.37 | 196.6 | 89 | − 2.37 | 100 | 0.51 |
3 | 0.51 | 0.22 | 0.40 | 0.37 | 0.39 | 0.42 | 0.35 | 0.40 | 184.1 | 90 | − 2.58 | 100 | 0.54 |
4 | 0.55 | 0.28 | 0.48 | 0.39 | 0.40 | 0.47 | 0.35 | 0.45 | 196.5 | 93 | − 2.28 | 100 | 0.57 |
5 | 0.53 | 0.27 | 0.50 | 0.51 | 0.41 | 0.54 | 0.37 | 0.43 | 159.3 | 98 | − 2.86 | 100 | 0.54 |
6 | 0.53 | 0.27 | 0.50 | 0.51 | 0.41 | 0.54 | 0.37 | 0.43 | 159.3 | 98 | − 2.86 | 100 | 0.54 |
7 | 0.51 | 0.30 | 0.52 | 0.49 | 0.47 | 0.60 | 0.38 | 0.44 | 85.2 | 99 | − 3.10 | 100 | 0.54 |
8 | 0.53 | 0.31 | 0.41 | 0.39 | 0.35 | 0.43 | 0.33 | 0.45 | 234.5 | 90 | − 2.19 | 100 | 0.59 |
9 | 0.55 | 0.33 | 0.50 | 0.50 | 0.44 | 0.55 | 0.35 | 0.46 | 71.8 | 99 | − 3.45 | 100 | 0.57 |
10 | 0.53 | 0.35 | 0.53 | 0.50 | 0.45 | 0.57 | 0.35 | 0.43 | 101.2 | 98 | − 2.92 | 100 | 0.57 |
11 | 0.55 | 0.35 | 0.56 | 0.48 | 0.45 | 0.64 | 0.39 | 0.50 | 33.3 | 99 | − 3.43 | 100 | 0.60 |
12 | 0.52 | 0.24 | 0.37 | 0.38 | 0.35 | 0.50 | 0.36 | 0.44 | 208.8 | 84 | − 1.89 | 100 | 0.59 |
13 | 0.51 | 0.23 | 0.43 | 0.49 | 0.38 | 0.55 | 0.38 | 0.38 | 182.9 | 96 | − 2.49 | 100 | 0.51 |
14 | 0.50 | 0.23 | 0.47 | 0.47 | 0.45 | 0.57 | 0.38 | 0.38 | 172.6 | 92 | − 2.30 | 100 | 0.47 |